FDA derails Acorda's marketing pitch, creating a crisis as flagship drug founders
Acorda just entered a world of hurt.
With its patent protection crumbling around its mainstay drug, the FDA has refused to file its application for CVT-301, the rescue program that was designated to take the lead drug’s place. The RTF creates an embarrassing and perhaps crippling problem for the biotech, which is fighting a last-ditch battle to maintain patent protection on its one big drug, Ampyra.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
